Receptor-interacting serine/threonine-protein kinase 3 (RIPK3) is the essential partner of RIPK1 in executing necroptosis, a programmed form of necrotic cell death. RIPK3 forms the necrosome core through RHIM domain-mediated interactions, leading to MLKL phosphorylation and plasma membrane disruption[1]. Unlike RIPK1, which functions as both a scaffold and a kinase, RIPK3 serves primarily as the kinase executioner of necroptosis[2].
In neurodegenerative diseases, RIPK3 activation contributes to neuronal death and neuroinflammation. Unlike RIPK1, RIPK3 has more restricted expression but plays a critical role in necroptotic execution in vulnerable neuronal populations[3].
| Domain | Position | Function |
|---|---|---|
| N-terminal kinase domain | Residues 1–286 | Serine/threonine kinase activity; catalytic core |
| Activation loop | Contains Thr182 | Autophosphorylation site required for activation |
| RHIM domain | Residues 386–467 | RIP homotypic interaction motif; mediates necrosome assembly |
| C-terminal region | Residues 468–527 | Regulatory elements; protein-protein interactions |
The RIPK3 kinase domain adopts a canonical protein kinase fold with:
The RHIM (RIP Homotypic Interaction Motif) is a ~20-residue sequence that mediates homotypic interactions between RIP family members:
Structural studies have revealed:
| Feature | Details |
|---|---|
| Gene | RIPK3 |
| Molecular Weight | 56.8 kDa (527 amino acids) |
| Subcellular Location | Cytoplasm; translocates to membrane upon activation |
| Expression | Restrictive — immune cells, neurons, some epithelial cells |
| PDB structures | 4M66 (kinase domain), 7Q5V (full-length) |
RIPK3 is the central executor of necroptosis, executing the cell death program once initiated by upstream signals[2:1]:
Beyond necroptosis, RIPK3 participates in several kinase-dependent and independent functions[2:2]:
Kinase-dependent (necroptosis-independent):
Kinase-independent (scaffold functions):
RIPK3 activation is increasingly recognized as a contributor to AD pathology[3:1]:
Pathological findings:
Mechanistic insights:
Evidence from models:
RIPK3-mediated necroptosis contributes to dopaminergic neuron death in PD[8]:
Evidence from human tissue:
Animal model evidence:
Key mechanisms:
Motor neurons are particularly susceptible to necroptosis[9]:
Clinical relevance:
Therapeutic implications:
Mechanisms of motor neuron vulnerability:
GSK'872 (GSK2399872A):[10]
HS1371:
Zabaditer:
Novel selective inhibitors (2024-2025):
| Challenge | Description |
|---|---|
| Kinase-independent functions | RIPK3 has scaffold roles beyond kinase activity; kinase inhibition may not fully block pathological RIPK3 |
| Alternative cell death | Blocking necroptosis may shift to apoptosis; dual targeting may be needed |
| Selectivity over RIPK1 | RIPK1 inhibitors exist but RIPK3-selective compounds are harder to develop due to structural similarity |
| Blood-brain barrier penetration | Required for CNS diseases; challenging for kinase inhibitors |
| Expression pattern | RIPK3 not expressed in all neurons; cell-type-specific targeting is needed |
| Timing window | Necroptosis is rapid once activated; prophylactic or early-intervention strategies may be most effective |
| Interactor | Relationship | Disease Relevance |
|---|---|---|
| RIPK1 | Necrosome partner; RHIM-mediated interaction | Necroptosis initiation and amplification |
| MLKL | Phosphorylation substrate | Executioner of membrane disruption |
| DAI/ZBP1 | RHIM-containing DNA sensor | Viral sensing; can trigger RIPK3 independently of RIPK1 |
| TRIF | TLR3/4 adaptor with RHIM | Downstream of pattern recognition receptors |
| PGAM5 | Mitochondrial phosphatase | Links necrosome to Drp1-mediated mitochondrial fission |
| Drp1 | Mitochondrial fission GTPase | Mitochondrial dysfunction in neurodegeneration |
| TAK1 | Kinase; activates NF-κB | NF-κB pathway; can inhibit or promote necroptosis depending on context |
| Caspase-8 | Cysteine protease | Cleaves RIPK1/RIPK3; blocks apoptosis and necroptosis |
| FADD | Death domain adaptor | Forms DISC with caspase-8; RIPK1-dependent |
| CYLD | Deubiquitinase | Removes RIPK1 ubiquitination; promotes necrosome formation |
| Feature | RIPK1 | RIPK3 |
|---|---|---|
| Expression | Ubiquitous across tissues | Restricted (immune cells, neurons, some epithelia) |
| Primary role | Scaffold → kinase; decision-maker | Kinase executioner; amplifier |
| Kinase activity | Moderate; modified by ubiquitination | High; autophosphorylation drives activation |
| Inhibitors in clinic | Yes (GSK2982772, DNL747, SAR443820) | No (research tools only: GSK'872, HS1371) |
| Genetic knockout phenotype | Perinatal lethal (embryonic/day 1) | Viable; susceptible to viral infection |
| Necrosome role | Initiator; recruits and activates RIPK3 | Executor; phosphorylates MLKL |
| RHIM presence | Yes | Yes |
| TLR signaling | Canonical adaptor | Alternative pathway |
Sun L, Wang H, Wang J, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012. ↩︎
Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol. 2013. ↩︎ ↩︎ ↩︎
Caccamo A, Branca C, Pistoia IR, et al. Necroptosis drives Alzheimer's disease pathology in vivo. J Neurosci. 2017. ↩︎ ↩︎ ↩︎
Fischer S, Werner A, Wagner S, et al. Small molecule RIPK3 inhibitors for neurological disease: current status and future directions. J Med Chem. 2025. ↩︎ ↩︎ ↩︎
Li J, McQuade T, Siemer AB, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell. 2012. ↩︎ ↩︎
Wu J, Huang Z, Ren J, et al. MLKL knockout mice demonstrate the indispensable role of MLKL in necroptosis. Proc Natl Acad Sci USA. 2013. ↩︎
Zhang J, Yang Y, He L, et al. Necroptosis and its role in the pathogenesis of Alzheimer's disease. Acta Neuropathol Commun. 2023. ↩︎
Wang X, Li Y, Chen J, et al. Dysregulated necroptosis signaling in Parkinson's disease: evidence from postmortem brain tissue. Neurobiol Dis. 2023. ↩︎
Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014. ↩︎ ↩︎
Kaiser WJ, Sridharan H, Huang C, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 2013. ↩︎